This story has been updated to include additional comments from Illumina.
NEW YORK – The US Federal Trade Commission said on Tuesday that it intends to challenge Illumina's plan to buy liquid biopsy firm Grail for $8 billion.
This story has been updated to include additional comments from Illumina.
NEW YORK – The US Federal Trade Commission said on Tuesday that it intends to challenge Illumina's plan to buy liquid biopsy firm Grail for $8 billion.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.